Robeco Institutional Asset Management B.V. Buys New Position in Kiniksa Pharmaceuticals International, plc $KNSA

Robeco Institutional Asset Management B.V. bought a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 8,436 shares of the company's stock, valued at approximately $233,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Toth Financial Advisory Corp purchased a new stake in Kiniksa Pharmaceuticals International in the second quarter valued at approximately $296,000. Wealth Enhancement Advisory Services LLC raised its stake in Kiniksa Pharmaceuticals International by 13.6% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 15,410 shares of the company's stock valued at $430,000 after purchasing an additional 1,846 shares in the last quarter. Pallas Capital Advisors LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the second quarter worth approximately $236,000. Voya Investment Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 54.4% during the first quarter. Voya Investment Management LLC now owns 30,866 shares of the company's stock worth $686,000 after acquiring an additional 10,878 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Kiniksa Pharmaceuticals International by 6.4% during the first quarter. Rhumbline Advisers now owns 62,700 shares of the company's stock worth $1,393,000 after acquiring an additional 3,745 shares in the last quarter. 53.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 42,000 shares of the business's stock in a transaction on Monday, September 29th. The shares were sold at an average price of $38.33, for a total transaction of $1,609,860.00. Following the sale, the chief operating officer owned 34,552 shares in the company, valued at approximately $1,324,378.16. The trade was a 54.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Thomas Malley sold 78,233 shares of the business's stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $33.09, for a total transaction of $2,588,729.97. Following the sale, the director owned 12,546 shares in the company, valued at approximately $415,147.14. This trade represents a 86.18% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 603,371 shares of company stock worth $20,434,869. Corporate insiders own 53.48% of the company's stock.

Analyst Upgrades and Downgrades

KNSA has been the topic of several research reports. Jefferies Financial Group lifted their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research note on Friday, October 3rd. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $42.00 to $45.00 and gave the stock an "overweight" rating in a research note on Thursday, September 25th. Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Finally, TD Cowen initiated coverage on shares of Kiniksa Pharmaceuticals International in a research note on Monday, September 29th. They set a "buy" rating and a $60.00 price target on the stock. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Kiniksa Pharmaceuticals International presently has a consensus rating of "Moderate Buy" and a consensus target price of $44.29.

Kiniksa Pharmaceuticals International Trading Up 0.5%

Shares of Kiniksa Pharmaceuticals International stock opened at $38.31 on Thursday. The company's fifty day simple moving average is $35.03 and its two-hundred day simple moving average is $28.97. The company has a market cap of $2.84 billion, a P/E ratio of 957.99 and a beta of 0.16. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $39.12.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Analysts predict that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.